MEDNAX (NYSE:MD) Rating Lowered to Neutral at Citigroup – Riverton Roll

MEDNAX (NYSE:MD) was downgraded by Citigroup from a buy rating to a neutral rating in a research note issued to investors on Friday, The Fly reports.

Other equities research analysts also recently issued reports about the company. TheStreet downgraded MEDNAX from a c- rating to a d rating in a report on Friday, November 1st. ValuEngine upgraded MEDNAX from a sell rating to a hold rating in a report on Friday. JPMorgan Chase & Co. lifted their price objective on MEDNAX from $26.00 to $33.00 and gave the stock a neutral rating in a report on Friday, December 20th. Bank of America downgraded MEDNAX from a neutral rating to an underperform rating and set a $19.00 price objective on the stock. in a report on Friday, September 6th. Finally, Mizuho set a $25.00 price objective on MEDNAX and gave the stock a hold rating in a report on Friday, November 1st. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the companys stock. MEDNAX has a consensus rating of Hold and a consensus target price of $27.92.

MEDNAX stock opened at $27.49 on Friday. The stocks 50 day moving average price is $26.82 and its 200 day moving average price is $24.08. The firm has a market capitalization of $2.34 billion, a PE ratio of 7.83, a price-to-earnings-growth ratio of 1.04 and a beta of 0.78. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.93 and a current ratio of 1.93. MEDNAX has a one year low of $19.93 and a one year high of $38.88.

MEDNAX (NYSE:MD) last released its quarterly earnings results on Friday, November 1st. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.83 by $0.08. The firm had revenue of $888.70 million for the quarter, compared to analyst estimates of $876.20 million. MEDNAX had a positive return on equity of 10.38% and a negative net margin of 40.86%. MEDNAXs revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the company posted $0.94 EPS. On average, analysts forecast that MEDNAX will post 3.03 earnings per share for the current fiscal year.

In other news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the businesss stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $22.88, for a total value of $114,400.00. Following the completion of the sale, the director now directly owns 10,821 shares in the company, valued at approximately $247,584.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.40% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. increased its holdings in shares of MEDNAX by 56.2% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 1,773 shares of the companys stock valued at $40,000 after acquiring an additional 638 shares during the last quarter. Parallel Advisors LLC grew its stake in MEDNAX by 78.4% during the 3rd quarter. Parallel Advisors LLC now owns 1,993 shares of the companys stock worth $45,000 after buying an additional 876 shares during the last quarter. US Bancorp DE grew its stake in MEDNAX by 38.5% during the 2nd quarter. US Bancorp DE now owns 5,657 shares of the companys stock worth $142,000 after buying an additional 1,572 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new position in MEDNAX during the 3rd quarter worth $161,000. Finally, ETF Managers Group LLC grew its stake in MEDNAX by 166.0% during the 2nd quarter. ETF Managers Group LLC now owns 6,845 shares of the companys stock worth $168,000 after buying an additional 4,272 shares during the last quarter. Institutional investors and hedge funds own 92.76% of the companys stock.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

See Also: Learning About the VIX Volatility Index

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post here:

MEDNAX (NYSE:MD) Rating Lowered to Neutral at Citigroup - Riverton Roll